Angiography is a leading cause of X-ray-related cancers and hospital acquired kidney injury. Kinepict introduced digital variance angiography with dramatic improvement in contrast to noise ratio allowing the development of safer procedures. It is implemented in and sold as a proprietary, patented, CE-marked software as a medical device. With $1.7M prior funding, Kinepict plans to develop a smart contrast agent and is looking for $10M investment.